3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Neoplasms
2
Neoplasm Metastasis
2
Breast Neoplasms
2
Non-small Cell Lung Cancer Metastatic
1
Colorectal Neoplasms
1
Interventions
Trastuzumab
304
Paclitaxel
257
Cyclophosphamide
251
Docetaxel
238
Capecitabine
176
Letrozole
163
Carboplatin
163
Fulvestrant
145
Doxorubicin
145
Bevacizumab
121
Anastrozole
106
Tamoxifen
102
exemestane
94
Vinorelbine
91
Epirubicin
90
pertuzumab
89
Gemcitabine
84
Lapatinib
80
Albumin-Bound Paclitaxel
74
Radiotherapy
71
pembrolizumab
70
palbociclib
64
130-nm albumin-bound paclitaxel
58
eribulin
56
Cisplatin
55
Everolimus
49
pyrotinib
45
Taxes
44
Goserelin
43
Neoadjuvant Therapy
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Breast Neoplasms
×
AZD 8931
×
Clear all
NCT02299999
2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2
Active not recruiting
1,460 enrolled
NCT01151215
2014-07-25
MINT
AstraZeneca
Phase 2
Terminated
482 enrolled
10 charts